For research use only. Not for therapeutic Use.
Pirepemat (IRL752) fumarate is a corticalpreferring catecholamine- and cognition-promoting agent. Pirepemat fumarate is used for the study of Parkinson’s disease[1][2].
IRL752 fumarate displays its highest in vitro affinities for 5-HT and NA-related targets[2].
IRL752 (3.7-100 µmol/kg, s.c.) fumarate has no significant effect on acute hyper-dopaminergic or hypo-glutamatergic motor responses, but reverses deficits resulting from hypomonoaminergic function[2].
| Catalog Number | I043722 |
| CAS Number | 2251806-70-7 |
| Synonyms | (E)-but-2-enedioic acid;(3S)-3-(2,3-difluorophenyl)-3-methoxypyrrolidine |
| Molecular Formula | C15H17F2NO5 |
| Purity | ≥95% |
| InChI | InChI=1S/C11H13F2NO.C4H4O4/c1-15-11(5-6-14-7-11)8-3-2-4-9(12)10(8)13;5-3(6)1-2-4(7)8/h2-4,14H,5-7H2,1H3;1-2H,(H,5,6)(H,7,8)/b;2-1+/t11-;/m1./s1 |
| InChIKey | FHXIIHXNSWGBPV-KGLGULAYSA-N |
| SMILES | COC1(CCNC1)C2=C(C(=CC=C2)F)F.C(=CC(=O)O)C(=O)O |
| Reference | [1]. Ipsen and IRLAB Enter Exclusive Worldwide Licensing Agreement Aimed to Improve the Lives of People Living with Parkinson’s Disease. [2]. S Hjorth, et al. (3 S)-3-(2,3-difluorophenyl)-3-methoxypyrrolidine (IRL752) -a Novel Cortical-Preferring Catecholamine Transmission- and Cognition-Promoting Agent. J Pharmacol Exp Ther. 2020 Sep;374(3):404-419. |
